ロード中...
Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up
Randomized trials of rituximab in primary membranous nephropathy (PMN) have not been conducted. We undertook a multicenter, randomized, controlled trial at 31 French hospitals (NCT01508468). Patients with biopsy-proven PMN and nephrotic syndrome after 6 months of nonimmunosuppressive antiproteinuric...
保存先:
| 出版年: | J Am Soc Nephrol |
|---|---|
| 主要な著者: | , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Nephrology
2017
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5198292/ https://ncbi.nlm.nih.gov/pubmed/27352623 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2016040449 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|